Pharming Group N.V.
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Show More...
-
Website http://www.pharming.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 10.60 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 TTM Earnings Per Share EUR -3.61 -3.28 -0.7 -0.15 -0.24 -0.42 -1.52 0.38 0.54 0.48 0.39 Dividends EUR Payout Ratio % * Shares Mil 5.0 7.0 21.0 40.0 41.0 42.0 50.0 65.0 67.0 68.0 69.0 Book Value Per Share * USD 2.62 3.09 Free Cash Flow Per Share * USD 1.04 Return on Assets % -55.19 -116.0 -62.42 -13.24 -17.56 -19.01 -54.58 13.13 16.35 11.61 8.08 Financial Leverage (Average) 6.27 1.86 2.42 4.62 8.84 3.47 2.18 2.28 2.08 Return on Equity % -353.53 -33.09 -37.1 -68.36 -345.62 62.05 43.5 26.01 18.22 Return on Invested Capital % -220.45 -30.05 -27.98 -20.74 -65.75 30.42 30.66 16.88 8.15 Interest Coverage -82.77 -8.28 -3.58 -31.95 -79.3 -3.89 -4.04 1.06 4.91 8.42 -339.66 Current Ratio 1.62 0.94 1.9 3.3 3.79 1.21 1.51 1.4 1.05 3.43 5.25 Quick Ratio 0.77 0.63 1.36 2.39 2.57 0.84 1.18 1.16 0.88 3.08 4.72 Debt/Equity 0.24 0.03 0.53 1.49 3.14 0.61 0.04 0.86 0.84